Aims. The purpose of this article was to review the current literature
pertaining to the use of mobile compression devices (MCDs) for venous
thromboembolism (VTE) following total joint arthroplasty (TJA),
and to discuss the results of data from our institution. Patients and Methods. Previous studies have illustrated higher rates of post-operative
wound complications, re-operation and re-admission with the use
of more aggressive anticoagulation regimens, such as warfarin and
factor Xa inhibitors. This highlights the importance of the safety,
as well as efficacy, of the chemoprophylactic regimen. Results. Studies have shown a symptomatic VTE rate of 0.92% with use of
MCDs for prophylaxis, which is comparable with rates seen with more
aggressive anticoagulation protocols. A prior prospective study
found that use of a pre-operative risk stratification protocol based on
personal history of deep vein thrombosis, family history of
With the established success of the National
Joint Registry and the emergence of a range of new national initiatives for
the capture of electronic data in the National Health Service, orthopaedic
surgery in the United Kingdom has found itself thrust to the forefront
of an information revolution. In this review we consider the benefits
and threats that this revolution poses, and how orthopaedic surgeons
should marshal their resources to ensure that this is a force for
good.
Following the publication in 2007 of the guidelines from the National Institute for Health and Clinical Excellence (NICE) for prophylaxis against venous thromboembolism (VTE) for patients undergoing surgery, concerns were raised by British orthopaedic surgeons as to the appropriateness of the recommendations for their clinical practice. In order to address these concerns NICE and the British Orthopaedic Association agreed to engage a representative panel of orthopaedic surgeons in the process of developing expanded
